Acer Therapeutics Inc. (ACER) financial statements (2021 and earlier)

Company profile

Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.)
NEWTON, MA 02458
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments612421631310
Cash and cash equivalents612421631310
Prepaid expense   1  0
Deferred costs      0
Other current assets    011
Other undisclosed current assets111   (1)
Total current assets:613431741411
Noncurrent Assets
Property, plant and equipment0000011
Intangible assets, net (including goodwill)8888   
Goodwill8888   
Other noncurrent assets0100  0
Other undisclosed noncurrent assets 000   
Total noncurrent assets:8988011
TOTAL ASSETS:1521512441412
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5362122
Accounts payable2110011
Accrued liabilities4252111
Debt    00 
Deferred revenue and credits  31
Other liabilities10     
Total current liabilities:6362153
Noncurrent Liabilities
Liabilities, other than long-term debt00    1
Deferred revenue and credits   1
Other liabilities00     
Total noncurrent liabilities:00    1
Total liabilities:6362154
Stockholders' equity
Stockholders' equity attributable to parent81845223107
Common stock0000000
Additional paid in capital107959248164163148
Accumulated deficit(99)(76)(47)(26)(161)(153)(141)
Total stockholders' equity:81845223107
TOTAL LIABILITIES AND EQUITY:1521512441412

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net 331
Gross profit:    331
Operating expenses(23)(30)(22)(14)(11)(15)(16)
Other undisclosed operating loss      (0)
Operating loss:(23)(30)(22)(14)(8)(12)(15)
Nonoperating income (expense)(0)00(0)000
Investment income, nonoperating 0    0
Foreign currency transaction gain (loss), before tax(0)0     
Other nonoperating income (expense)  0(0)000
Interest and debt expense      (0)
Net loss:(23)(29)(21)(14)(8)(12)(15)
Other undisclosed net income attributable to parent    00 
Net loss available to common stockholders, diluted:(23)(29)(21)(14)(8)(12)(15)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(23)(29)(21)(14)(8)(12)(15)
Comprehensive loss, net of tax, attributable to parent:(23)(29)(21)(14)(8)(12)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: